Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	JUN kinase activity	MAPK8 MAPK9	4.51e-06	3	25	2	GO:0004705
GeneOntologyMolecularFunction	MAP kinase activity	MAPK8 MAPK9	1.79e-04	16	25	2	GO:0004707
GeneOntologyMolecularFunction	phosphotransferase activity, alcohol group as acceptor	PRKACG PNKP PRKDC MAPK8 MAPK9 GRK7	1.95e-04	709	25	6	GO:0016773
GeneOntologyMolecularFunction	protein serine/threonine kinase activity	PRKACG PRKDC MAPK8 MAPK9 GRK7	2.00e-04	446	25	5	GO:0004674
GeneOntologyMolecularFunction	kinase activity	PRKACG PNKP PRKDC MAPK8 MAPK9 GRK7	2.92e-04	764	25	6	GO:0016301
GeneOntologyMolecularFunction	protein kinase activity	PRKACG PRKDC MAPK8 MAPK9 GRK7	7.77e-04	600	25	5	GO:0004672
GeneOntologyMolecularFunction	transferase activity, transferring phosphorus-containing groups	PRKACG PNKP PRKDC MAPK8 MAPK9 GRK7	8.68e-04	938	25	6	GO:0016772
GeneOntologyMolecularFunction	protein serine kinase activity	PRKACG PRKDC MAPK8 MAPK9	1.00e-03	363	25	4	GO:0106310
GeneOntologyMolecularFunction	protein serine/threonine/tyrosine kinase activity	MAPK8 MAPK9	1.57e-03	47	25	2	GO:0004712
GeneOntologyMolecularFunction	damaged DNA binding	PNKP MPG	4.93e-03	84	25	2	GO:0003684
GeneOntologyMolecularFunction	molecular carrier activity	IPO9 TF	8.02e-03	108	25	2	GO:0140104
GeneOntologyBiologicalProcess	protein localization to tricellular tight junction	MAPK8 MAPK9	8.45e-06	4	25	2	GO:0061833
GeneOntologyBiologicalProcess	regulation of circadian rhythm	PRKDC MAPK8 MAPK9 RBM4B	2.00e-05	135	25	4	GO:0042752
GeneOntologyBiologicalProcess	response to radiation	PNKP PRKDC MAPK8 MAPK9 RBM4B GRK7	2.44e-05	503	25	6	GO:0009314
GeneOntologyBiologicalProcess	positive regulation of podosome assembly	MAPK8 MAPK9	1.09e-04	13	25	2	GO:0071803
GeneOntologyBiologicalProcess	positive regulation of neural precursor cell proliferation	MAPK8 TF NOTCH2	1.22e-04	80	25	3	GO:2000179
GeneOntologyBiologicalProcess	positive regulation of double-strand break repair via nonhomologous end joining	PNKP PRKDC	1.90e-04	17	25	2	GO:2001034
GeneOntologyBiologicalProcess	regulation of podosome assembly	MAPK8 MAPK9	1.90e-04	17	25	2	GO:0071801
GeneOntologyBiologicalProcess	circadian rhythm	PRKDC MAPK8 MAPK9 RBM4B	2.12e-04	248	25	4	GO:0007623
GeneOntologyBiologicalProcess	protein localization to cell-cell junction	MAPK8 MAPK9	3.83e-04	24	25	2	GO:0150105
GeneOntologyBiologicalProcess	Fc-epsilon receptor signaling pathway	MAPK8 MAPK9	4.16e-04	25	25	2	GO:0038095
GeneOntologyBiologicalProcess	podosome assembly	MAPK8 MAPK9	4.50e-04	26	25	2	GO:0071800
GeneOntologyBiologicalProcess	cellular senescence	PRKDC MAPK8 MAPK9	4.86e-04	128	25	3	GO:0090398
GeneOntologyBiologicalProcess	regulation of cytoplasmic pattern recognition receptor signaling pathway	PRKDC MAPK8 SLC15A2	4.97e-04	129	25	3	GO:0039531
GeneOntologyBiologicalProcess	regulation of neural precursor cell proliferation	MAPK8 TF NOTCH2	5.68e-04	135	25	3	GO:2000177
MousePheno	decreased T cell apoptosis	PRKDC MAPK8 MAPK9	1.46e-05	34	20	3	MP:0006414
MousePheno	decreased cardiomyocyte apoptosis	MAPK8 MAPK9	5.42e-05	8	20	2	MP:0003223
MousePheno	abnormal CD4-positive T cell differentiation	PRKDC MAPK8 MAPK9	1.24e-04	69	20	3	MP:0008076
MousePheno	intestine polyps	CDX2 PRKDC	1.50e-04	13	20	2	MP:0008011
MousePheno	gastrointestinal tract polyps	CDX2 PRKDC	1.75e-04	14	20	2	MP:0010352
MousePheno	decreased apoptosis	CDX2 PRKDC MAPK8 MAPK9	2.33e-04	219	20	4	MP:0006043
MousePheno	abnormal cell proliferation	TRPV1 PNKP CDX2 PRKDC LZTR1 MAPK8 MAPK9 NOTCH2	2.41e-04	1294	20	8	MP:0000350
MousePheno	decreased cell death	CDX2 PRKDC MAPK8 MAPK9	2.50e-04	223	20	4	MP:0012555
MousePheno	abnormal keratohyalin granule morphology	MAPK8 MAPK9	2.61e-04	17	20	2	MP:0009602
MousePheno	abnormal T cell apoptosis	PRKDC MAPK8 MAPK9	2.99e-04	93	20	3	MP:0006412
MousePheno	abnormal T-helper 1 cell differentiation	MAPK8 MAPK9	4.02e-04	21	20	2	MP:0008088
MousePheno	decreased cell proliferation	PNKP CDX2 PRKDC MAPK8 MAPK9 NOTCH2	4.38e-04	739	20	6	MP:0000352
Domain	MAPK_JNK	MAPK8 MAPK9	1.72e-05	5	25	2	IPR008351
Domain	FAT	TMTC1 PRKDC	2.57e-05	6	25	2	PF02259
Domain	PIK-rel_kinase_FAT	TMTC1 PRKDC	2.57e-05	6	25	2	IPR003151
Domain	MAP_kinase_CS	MAPK8 MAPK9	1.13e-04	12	25	2	IPR003527
Domain	MAPK	MAPK8 MAPK9	1.13e-04	12	25	2	PS01351
Domain	Kinase-like_dom	PRKACG PRKDC MAPK8 MAPK9 GRK7	6.63e-04	542	25	5	IPR011009
Domain	Ser/Thr_kinase_AS	PRKACG MAPK8 MAPK9 GRK7	1.21e-03	357	25	4	IPR008271
Domain	S_TKc	PRKACG MAPK8 MAPK9 GRK7	1.23e-03	359	25	4	SM00220
Domain	PROTEIN_KINASE_ST	PRKACG MAPK8 MAPK9 GRK7	1.27e-03	362	25	4	PS00108
Domain	Pkinase	PRKACG MAPK8 MAPK9 GRK7	1.54e-03	381	25	4	PF00069
Domain	AGC-kinase_C	PRKACG GRK7	2.53e-03	56	25	2	IPR000961
Domain	AGC_KINASE_CTER	PRKACG GRK7	2.53e-03	56	25	2	PS51285
Domain	S_TK_X	PRKACG GRK7	2.53e-03	56	25	2	SM00133
Domain	PROTEIN_KINASE_ATP	PRKACG MAPK8 MAPK9 GRK7	3.02e-03	459	25	4	PS00107
Domain	Prot_kinase_dom	PRKACG MAPK8 MAPK9 GRK7	3.79e-03	489	25	4	IPR000719
Domain	PROTEIN_KINASE_DOM	PRKACG MAPK8 MAPK9 GRK7	3.91e-03	493	25	4	PS50011
Pathway	WP_CANNABINOID_RECEPTOR_SIGNALING	PRKACG MAPK8 MAPK9	1.35e-05	29	23	3	M39676
Pathway	KEGG_MEDICUS_ENV_FACTOR_PARAQUAT_TO_FAS_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	2.54e-05	5	23	2	M49021
Pathway	KEGG_MEDICUS_PATHOGEN_HTLV_1_TAX_TO_TNF_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	2.54e-05	5	23	2	M49005
Pathway	KEGG_MEDICUS_PATHOGEN_HIV_VPR_TAT_TO_TNF_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	2.54e-05	5	23	2	M47570
Pathway	WP_OSTEOBLAST_DIFFERENTIATION_AND_RELATED_DISEASES	PRKDC MAPK8 MAPK9 NOTCH2	3.65e-05	118	23	4	M39852
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_HTT_TO_TNF_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	3.80e-05	6	23	2	M47680
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_IRE1A_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	3.80e-05	6	23	2	M47698
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_DJ1_TO_FAS_JNK_SIGNALING_PATWHAY	MAPK8 MAPK9	3.80e-05	6	23	2	M47712
Pathway	KEGG_MEDICUS_REFERENCE_IRE1A_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	5.32e-05	7	23	2	M47697
Pathway	KEGG_MEDICUS_REFERENCE_FAS_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	5.32e-05	7	23	2	M47711
Pathway	KEGG_MEDICUS_ENV_FACTOR_METALS_TO_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	7.09e-05	8	23	2	M47814
Pathway	REACTOME_ACTIVATION_OF_THE_AP_1_FAMILY_OF_TRANSCRIPTION_FACTORS	MAPK8 MAPK9	1.14e-04	10	23	2	MM15135
Pathway	REACTOME_ACTIVATION_OF_THE_AP_1_FAMILY_OF_TRANSCRIPTION_FACTORS	MAPK8 MAPK9	1.14e-04	10	23	2	M13962
Pathway	KEGG_MEDICUS_REFERENCE_MLK_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	1.66e-04	12	23	2	M47929
Pathway	KEGG_MEDICUS_REFERENCE_EGF_EGFR_RAS_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	1.96e-04	13	23	2	M47594
Pathway	WP_CIRCADIAN_RHYTHM_GENES	PRKDC MAPK8 MAPK9 RBM4B	2.87e-04	201	23	4	M39605
Pathway	KEGG_MEDICUS_REFERENCE_TNF_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	3.01e-04	16	23	2	M47569
Pathway	PID_DNA_PK_PATHWAY	PNKP PRKDC	3.01e-04	16	23	2	M42
Pathway	PID_REG_GR_PATHWAY	PRKACG MAPK8 MAPK9	3.09e-04	82	23	3	M115
Pathway	WP_CANONICAL_AND_NONCANONICAL_TGFB_SIGNALING	MAPK8 MAPK9	3.41e-04	17	23	2	M39686
Pathway	KEGG_PROGESTERONE_MEDIATED_OOCYTE_MATURATION	PRKACG MAPK8 MAPK9	3.43e-04	85	23	3	M3578
Pathway	KEGG_MEDICUS_REFERENCE_IL1_IL1R_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	4.28e-04	19	23	2	M47471
Pathway	KEGG_MEDICUS_REFERENCE_REGULATION_OF_GF_RTK_RAS_ERK_SIGNALING_PTP	MAPK8 MAPK9	4.75e-04	20	23	2	M47928
Pathway	KEGG_GNRH_SIGNALING_PATHWAY	PRKACG MAPK8 MAPK9	5.70e-04	101	23	3	M1979
Pathway	REACTOME_JNK_C_JUN_KINASES_PHOSPHORYLATION_AND_ACTIVATION_MEDIATED_BY_ACTIVATED_HUMAN_TAK1	MAPK8 MAPK9	5.77e-04	22	23	2	M859
Pathway	REACTOME_JNK_C_JUN_KINASES_PHOSPHORYLATION_AND_ACTIVATION_MEDIATED_BY_ACTIVATED_HUMAN_TAK1	MAPK8 MAPK9	6.31e-04	23	23	2	MM15134
Pathway	KEGG_MEDICUS_REFERENCE_TLR2_4_MAPK_SIGNALING_PATHWAY	MAPK8 MAPK9	8.08e-04	26	23	2	M47565
Pathway	WP_NANOPARTICLEMEDIATED_ACTIVATION_OF_RECEPTOR_SIGNALING	MAPK8 MAPK9	9.38e-04	28	23	2	M39572
Pathway	REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_MEDIATED_BY_MAP_KINASES	MAPK8 MAPK9	9.38e-04	28	23	2	MM15132
Pathway	BIOCARTA_TNFR1_PATHWAY	PRKDC MAPK8	9.38e-04	28	23	2	MM1516
Pathway	BIOCARTA_FAS_PATHWAY	PRKDC MAPK8	9.38e-04	28	23	2	MM1396
Pathway	WP_DNA_REPAIR_PATHWAYS_FULL_NETWORK	PNKP PRKDC MPG	9.41e-04	120	23	3	M40049
Pathway	KEGG_MEDICUS_PATHOGEN_KSHV_VGPCR_TO_GNB_G_PI3K_JNK_SIGNALING_PATHWAY	MAPK8 MAPK9	1.01e-03	29	23	2	M47466
Pathway	BIOCARTA_TNFR1_PATHWAY	PRKDC MAPK8	1.01e-03	29	23	2	M3618
Pathway	BIOCARTA_FAS_PATHWAY	PRKDC MAPK8	1.08e-03	30	23	2	M9503
Pathway	WP_BASE_EXCISION_REPAIR	PNKP MPG	1.15e-03	31	23	2	M39861
Pathway	PID_NEPHRIN_NEPH1_PATHWAY	MAPK8 MAPK9	1.15e-03	31	23	2	M193
Pathway	PID_CD40_PATHWAY	MAPK8 MAPK9	1.15e-03	31	23	2	M45
Pathway	REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_MEDIATED_BY_MAP_KINASES	MAPK8 MAPK9	1.15e-03	31	23	2	M15195
Pathway	PID_IL12_STAT4_PATHWAY	MAPK8 MAPK9	1.23e-03	32	23	2	M290
Pathway	PID_WNT_NONCANONICAL_PATHWAY	MAPK8 MAPK9	1.23e-03	32	23	2	M23
Pathway	REACTOME_DNA_REPAIR	PNKP PRKDC MAPK8 MPG	1.31e-03	301	23	4	MM15433
Pathway	KEGG_INSULIN_SIGNALING_PATHWAY	PRKACG MAPK8 MAPK9	1.38e-03	137	23	3	M18155
Pathway	WP_13Q1212_COPY_NUMBER_VARIATION	MAPK8 MAPK9	1.38e-03	34	23	2	M48103
Pathway	SIG_CD40PATHWAYMAP	MAPK8 MAPK9	1.38e-03	34	23	2	M12705
Pathway	WP_WNT_SIGNALING_IN_KIDNEY_DISEASE	MAPK8 MAPK9	1.55e-03	36	23	2	M39699
Pathway	WP_HOSTPATHOGEN_INTERACTION_OF_HUMAN_CORONAVIRUSES_MAPK_SIGNALING	MAPK8 MAPK9	1.55e-03	36	23	2	M39908
Pathway	WP_FAS_PATHWAY_AND_STRESS_INDUCTION_OF_HSP_REGULATION	PRKDC MAPK8	1.55e-03	36	23	2	MM15967
Pathway	WP_NEOVASCULARIZATION_PROCESSES	MAPK8 MAPK9	1.64e-03	37	23	2	M39506
Pathway	REACTOME_OXIDATIVE_STRESS_INDUCED_SENESCENCE	MAPK8 MAPK9	1.64e-03	37	23	2	MM14899
Pathway	PID_FAS_PATHWAY	MAPK8 MAPK9	1.73e-03	38	23	2	M94
Pathway	REACTOME_RESOLUTION_OF_ABASIC_SITES_AP_SITES	PNKP MPG	1.73e-03	38	23	2	M27701
Pathway	REACTOME_RESOLUTION_OF_ABASIC_SITES_AP_SITES	PNKP MPG	1.82e-03	39	23	2	MM17222
Pathway	KEGG_WNT_SIGNALING_PATHWAY	PRKACG MAPK8 MAPK9	1.82e-03	151	23	3	M19428
Pathway	REACTOME_DNA_REPAIR	PNKP PRKDC MAPK8 MPG	1.88e-03	332	23	4	M15434
Pathway	WP_TNFRELATED_WEAK_INDUCER_OF_APOPTOSIS_TWEAK_SIGNALING	MAPK8 MAPK9	2.11e-03	42	23	2	M39452
Pathway	WP_FAS_LIGAND_PATHWAY_AND_STRESS_INDUCTION_OF_HEAT_SHOCK_PROTEINS	PRKDC MAPK8	2.31e-03	44	23	2	M39673
Pathway	PID_ERBB2_ERBB3_PATHWAY	MAPK8 MAPK9	2.31e-03	44	23	2	M175
Pathway	WP_WNT_SIGNALING_IN_KIDNEY_DISEASE	MAPK8 MAPK9	2.31e-03	44	23	2	MM15878
Pathway	WP_TRANSLATION_INHIBITORS_IN_CHRONICALLY_ACTIVATED_PDGFRA_CELLS	MAPK8 MAPK9	2.52e-03	46	23	2	M39805
Pathway	WP_IL26_SIGNALING	MAPK8 MAPK9	2.63e-03	47	23	2	M48074
Pathway	KEGG_TYPE_II_DIABETES_MELLITUS	MAPK8 MAPK9	2.63e-03	47	23	2	M19708
Pathway	WP_MECHANOREGULATION_AND_PATHOLOGY_OF_YAPTAZ_VIA_HIPPO_AND_NONHIPPO_MECHANISMS	MAPK8 MAPK9	2.63e-03	47	23	2	M39829
Pathway	WP_THYMIC_STROMAL_LYMPHOPOIETIN_TSLP_SIGNALING	MAPK8 MAPK9	2.63e-03	47	23	2	M39380
Pathway	PID_FOXO_PATHWAY	MAPK8 MAPK9	2.86e-03	49	23	2	M136
Pathway	WP_INTERLEUKIN1_IL1_STRUCTURAL_PATHWAY	MAPK8 MAPK9	2.86e-03	49	23	2	M39543
Pathway	BIOCARTA_NFAT_PATHWAY	PRKACG MAPK8	3.09e-03	51	23	2	M2288
Pathway	WP_WNT_SIGNALING_WP363	MAPK8 MAPK9	3.09e-03	51	23	2	M39721
Pathway	WP_RAS_SIGNALING	PRKACG MAPK8 MAPK9	3.20e-03	184	23	3	M39764
Pathway	PID_NFAT_3PATHWAY	MAPK8 MAPK9	3.34e-03	53	23	2	M113
Pathway	PID_RAC1_PATHWAY	MAPK8 MAPK9	3.46e-03	54	23	2	M278
Pathway	WP_IL1_SIGNALING	MAPK8 MAPK9	3.59e-03	55	23	2	M39346
Pathway	PID_IL2_1PATHWAY	MAPK8 MAPK9	3.59e-03	55	23	2	M122
Pathway	WP_RANKLRANK_SIGNALING	MAPK8 MAPK9	3.59e-03	55	23	2	M39667
Pathway	BIOCARTA_HIVNEF_PATHWAY	PRKDC MAPK8	3.72e-03	56	23	2	MM1406
Pathway	BIOCARTA_HIVNEF_PATHWAY	PRKDC MAPK8	3.72e-03	56	23	2	M13968
Pathway	PID_ATF2_PATHWAY	MAPK8 MAPK9	4.12e-03	59	23	2	M166
Pathway	PID_P53_REGULATION_PATHWAY	MAPK8 MAPK9	4.12e-03	59	23	2	M261
Pathway	PID_FAK_PATHWAY	MAPK8 MAPK9	4.12e-03	59	23	2	M281
Pathway	REACTOME_INTERLEUKIN_17_SIGNALING	MAPK8 MAPK9	4.12e-03	59	23	2	MM15128
Pathway	WP_NOVEL_INTRACELLULAR_COMPONENTS_OF_RIGILIKE_RECEPTOR_PATHWAY	MAPK8 MAPK9	4.26e-03	60	23	2	M39583
Pathway	REACTOME_FCERI_MEDIATED_MAPK_ACTIVATION	MAPK8 MAPK9	4.26e-03	60	23	2	MM14913
Pathway	KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY	MAPK8 MAPK9	4.54e-03	62	23	2	M15569
Pathway	KEGG_COLORECTAL_CANCER	MAPK8 MAPK9	4.54e-03	62	23	2	M14631
Pathway	WP_ONCOSTATIN_M_SIGNALING	MAPK8 MAPK9	4.98e-03	65	23	2	M39562
Pathway	PID_CD8_TCR_DOWNSTREAM_PATHWAY	MAPK8 MAPK9	4.98e-03	65	23	2	M272
Pathway	WP_AGERAGE_PATHWAY	MAPK8 MAPK9	5.13e-03	66	23	2	M39420
Pathway	REACTOME_BASE_EXCISION_REPAIR	PNKP MPG	5.28e-03	67	23	2	MM15429
Pathway	KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY	MAPK8 MAPK9	5.28e-03	67	23	2	M10462
Pathway	WP_RAC1PAK1P38MMP2_PATHWAY	MAPK8 MAPK9	5.43e-03	68	23	2	M39456
Pathway	KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION	MAPK8 MAPK9	5.43e-03	68	23	2	M16848
Pathway	PID_P75_NTR_PATHWAY	MAPK8 MAPK9	5.43e-03	68	23	2	M153
Pathway	WP_UROTENSINIIMEDIATED_SIGNALING	MAPK8 MAPK9	5.59e-03	69	23	2	M48052
Pathway	KEGG_PANCREATIC_CANCER	MAPK8 MAPK9	5.75e-03	70	23	2	M9726
Pathway	PID_CDC42_PATHWAY	MAPK8 MAPK9	5.75e-03	70	23	2	M81
Pathway	REACTOME_INTERLEUKIN_17_SIGNALING	MAPK8 MAPK9	5.91e-03	71	23	2	M27382
Pathway	KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY	MAPK8 MAPK9	5.91e-03	71	23	2	M15913
Pathway	WP_CHROMOSOMAL_AND_MICROSATELLITE_INSTABILITY_IN_COLORECTAL_CANCER	MAPK8 MAPK9	6.24e-03	73	23	2	M39758
Pathway	WP_NONGENOMIC_ACTIONS_OF_125_DIHYDROXYVITAMIN_D3	MAPK8 MAPK9	6.57e-03	75	23	2	M39568
Pathway	BIOCARTA_MAPK_PATHWAY	MAPK8 MAPK9	6.74e-03	76	23	2	MM1433
Pubmed	Involvement of DNA-dependent protein kinase in regulation of stress-induced JNK activation.	PRKDC MAPK8 MAPK9	1.31e-09	4	25	3	11749722
Pubmed	JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate.	PRKDC MAPK8 MAPK9	1.15e-08	7	25	3	22753496
Pubmed	JNK-dependent Stat3 phosphorylation contributes to Akt activation in response to arsenic exposure.	MAPK8 MAPK9	4.96e-07	2	25	2	22696236
Pubmed	C-Jun N-terminal kinase (JNK) isoforms play differing roles in otitis media.	MAPK8 MAPK9	4.96e-07	2	25	2	25311344
Pubmed	Genetic inhibition or activation of JNK1/2 protects the myocardium from ischemia-reperfusion-induced cell death in vivo.	MAPK8 MAPK9	4.96e-07	2	25	2	16043490
Pubmed	Combined Activities of JNK1 and JNK2 in Hepatocytes Protect Against Toxic Liver Injury.	MAPK8 MAPK9	4.96e-07	2	25	2	26708719
Pubmed	Ablation of the spindle assembly checkpoint by a compound targeting Mps1.	MAPK8 MAPK9	4.96e-07	2	25	2	16113653
Pubmed	c-Jun N-terminal kinase 1 is deleterious to the function and survival of murine pancreatic islets.	MAPK8 MAPK9	4.96e-07	2	25	2	18853132
Pubmed	Ultrafine particles from diesel engines induce vascular oxidative stress via JNK activation.	MAPK8 MAPK9	4.96e-07	2	25	2	19154785
Pubmed	Role of the MAPK/cJun NH2-terminal kinase signaling pathway in starvation-induced autophagy.	MAPK8 MAPK9	4.96e-07	2	25	2	29950132
Pubmed	Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance.	MAPK8 MAPK9	4.96e-07	2	25	2	16818881
Pubmed	Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells.	MAPK8 MAPK9	4.96e-07	2	25	2	23912840
Pubmed	Suppression of inflammatory cytokine production by carbon monoxide involves the JNK pathway and AP-1.	MAPK8 MAPK9	4.96e-07	2	25	2	12857751
Pubmed	JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis.	MAPK8 MAPK9	4.96e-07	2	25	2	21839715
Pubmed	JNK is required for maintaining the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells.	MAPK8 MAPK9	4.96e-07	2	25	2	26235742
Pubmed	Prevention of steatosis by hepatic JNK1.	MAPK8 MAPK9	4.96e-07	2	25	2	19945406
Pubmed	C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma.	MAPK8 MAPK9	4.96e-07	2	25	2	12538493
Pubmed	Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling.	MAPK8 MAPK9	4.96e-07	2	25	2	19596001
Pubmed	Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma.	MAPK8 MAPK9	4.96e-07	2	25	2	17908987
Pubmed	c-Jun N-terminal kinase 1/2 activation by tumor necrosis factor-alpha induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists.	MAPK8 MAPK9	4.96e-07	2	25	2	19567513
Pubmed	Increased JNK in males compared with females in a rodent model of abdominal aortic aneurysm.	MAPK8 MAPK9	4.96e-07	2	25	2	22316675
Pubmed	Defective antiviral CD8 T-cell response and viral clearance in the absence of c-Jun N-terminal kinases.	MAPK8 MAPK9	4.96e-07	2	25	2	24673683
Pubmed	c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.	MAPK8 MAPK9	4.96e-07	2	25	2	11435459
Pubmed	[Sodium butyrate do not induce the program of premature senescence in transformants with JNK1,2 knockout].	MAPK8 MAPK9	4.96e-07	2	25	2	19140343
Pubmed	Modulation of the response of prostate cancer cell lines to cisplatin treatment using small interfering RNA.	MAPK8 MAPK9	4.96e-07	2	25	2	23900581
Pubmed	Inhibition of c-Jun N-terminal kinase attenuates low shear stress-induced atherogenesis in apolipoprotein E-deficient mice.	MAPK8 MAPK9	4.96e-07	2	25	2	21629969
Pubmed	c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis.	MAPK8 MAPK9	4.96e-07	2	25	2	15572687
Pubmed	Hepatotoxicity mediated by pyrazole (cytochrome P450 2E1) plus tumor necrosis factor alpha treatment occurs in c-Jun N-terminal kinase 2-/- but not in c-Jun N-terminal kinase 1-/- mice.	MAPK8 MAPK9	4.96e-07	2	25	2	21748763
Pubmed	Purinergic (ATP) signaling stimulates JNK1 but not JNK2 MAPK in osteoblast-like cells: contribution of intracellular Ca2+ release, stress activated and L-voltage-dependent calcium influx, PKC and Src kinases.	MAPK8 MAPK9	4.96e-07	2	25	2	18625195
Pubmed	The JNKs differentially regulate RNA polymerase III transcription by coordinately modulating the expression of all TFIIIB subunits.	MAPK8 MAPK9	4.96e-07	2	25	2	19620725
Pubmed	Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway.	MAPK8 MAPK9	4.96e-07	2	25	2	16571730
Pubmed	JNK inhibition reduces apoptosis and neovascularization in a murine model of age-related macular degeneration.	MAPK8 MAPK9	4.96e-07	2	25	2	23341606
Pubmed	c-Jun N-terminal kinase 2 promotes enterocyte survival and goblet cell differentiation in the inflamed intestine.	MAPK8 MAPK9	4.96e-07	2	25	2	28098247
Pubmed	c-Jun N-terminal kinase is upregulated in patients with hypospadias.	MAPK8 MAPK9	4.96e-07	2	25	2	23273084
Pubmed	An initial phase of JNK activation inhibits cell death early in the endoplasmic reticulum stress response.	MAPK8 MAPK9	4.96e-07	2	25	2	27122189
Pubmed	JNK2 up-regulates hypoxia-inducible factors and contributes to hypoxia-induced erythropoiesis and pulmonary hypertension.	MAPK8 MAPK9	4.96e-07	2	25	2	29118187
Pubmed	Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2.	MAPK8 MAPK9	4.96e-07	2	25	2	10559486
Pubmed	c-Jun N-terminal kinase activity is required for efficient respiratory syncytial virus production.	MAPK8 MAPK9	4.96e-07	2	25	2	28062184
Pubmed	JNK regulates muscle remodeling via myostatin/SMAD inhibition.	MAPK8 MAPK9	4.96e-07	2	25	2	30072727
Pubmed	c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation.	MAPK8 MAPK9	4.96e-07	2	25	2	11927626
Pubmed	c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8(+) T cell-mediated antiviral immunity.	MAPK8 MAPK9	4.96e-07	2	25	2	11927625
Pubmed	Efficient keratinocyte differentiation strictly depends on JNK-induced soluble factors in fibroblasts.	MAPK8 MAPK9	4.96e-07	2	25	2	24335928
Pubmed	Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: evidence that mitotic Bcl-2 phosphorylation is JNK-independent.	MAPK8 MAPK9	4.96e-07	2	25	2	14704147
Pubmed	Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells.	MAPK8 MAPK9	4.96e-07	2	25	2	14724588
Pubmed	Coordination of JNK1 and JNK2 is critical for GADD45alpha induction and its mediated cell apoptosis in arsenite responses.	MAPK8 MAPK9	4.96e-07	2	25	2	16973625
Pubmed	Differential roles of JNK in ConA/GalN and ConA-induced liver injury in mice.	MAPK8 MAPK9	4.96e-07	2	25	2	18772342
Pubmed	c-Jun NH2-terminal kinase-2 mediates osmotic stress-induced tight junction disruption in the intestinal epithelium.	MAPK8 MAPK9	4.96e-07	2	25	2	20595622
Pubmed	c-Jun NH2-terminal kinase is required for lineage-specific differentiation but not stem cell self-renewal.	MAPK8 MAPK9	4.96e-07	2	25	2	20065035
Pubmed	Inhibited neurogenesis in JNK1-deficient embryonic stem cells.	MAPK8 MAPK9	4.96e-07	2	25	2	16314504
Pubmed	c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1.	MAPK8 MAPK9	4.96e-07	2	25	2	33526844
Pubmed	JNK1 and 2 play a negative role in reprogramming to pluripotent stem cells by suppressing Klf4 activity.	MAPK8 MAPK9	4.96e-07	2	25	2	24211391
Pubmed	Protective role of c-Jun N-terminal kinase-2 (JNK2) in ibuprofen-induced acute liver injury.	MAPK8 MAPK9	4.96e-07	2	25	2	30264435
Pubmed	Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of type I diabetes.	PRKDC MAPK9	4.96e-07	2	25	2	15867147
Pubmed	Decreased expression of phosphorylated JNK in breast infiltrating ductal carcinoma is associated with a better overall survival.	MAPK8 MAPK9	4.96e-07	2	25	2	16381010
Pubmed	Protective role of c-Jun N-terminal kinase 2 in acetaminophen-induced liver injury.	MAPK8 MAPK9	4.96e-07	2	25	2	18586006
Pubmed	JNK/SAPK Signaling Is Essential for Efficient Reprogramming of Human Fibroblasts to Induced Pluripotent Stem Cells.	MAPK8 MAPK9	4.96e-07	2	25	2	26867034
Pubmed	c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D.	MAPK8 MAPK9	4.96e-07	2	25	2	19339050
Pubmed	Jun N-terminal kinase 1 regulates epithelial-to-mesenchymal transition induced by TGF-beta1.	MAPK8 MAPK9	4.96e-07	2	25	2	18334556
Pubmed	A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis.	MAPK8 MAPK9	4.96e-07	2	25	2	17202416
Pubmed	Deletion of JNK Enhances Senescence in Joint Tissues and Increases the Severity of Age-Related Osteoarthritis in Mice.	MAPK8 MAPK9	4.96e-07	2	25	2	32418287
Pubmed	The role of JNK in the development of hepatocellular carcinoma.	MAPK8 MAPK9	4.96e-07	2	25	2	21406557
Pubmed	JNK1/2 regulates ER-mitochondrial Ca2+ cross-talk during IL-1β-mediated cell death in RINm5F and human primary β-cells.	MAPK8 MAPK9	4.96e-07	2	25	2	23615449
Pubmed	Genetic deletion of JNK1 and JNK2 aggravates the DSS-induced colitis in mice.	MAPK8 MAPK9	4.96e-07	2	25	2	17365404
Pubmed	Signal transduction by the JNK group of MAP kinases.	MAPK8 MAPK9	4.96e-07	2	25	2	11057897
Pubmed	Effect of Jun N-terminal kinase 1 and 2 on the replication of Penicillium marneffei in human macrophages.	MAPK8 MAPK9	4.96e-07	2	25	2	25792289
Pubmed	Silencing Jnk1 and Jnk2 accelerates basal lipolysis and promotes fatty acid re-esterification in mouse adipocytes.	MAPK8 MAPK9	4.96e-07	2	25	2	18528680
Pubmed	Oppositional regulation of Noxa by JNK1 and JNK2 during apoptosis induced by proteasomal inhibitors.	MAPK8 MAPK9	1.49e-06	3	25	2	23593480
Pubmed	JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy.	MAPK8 MAPK9	1.49e-06	3	25	2	30685843
Pubmed	Overexpression or ablation of JNK in skeletal muscle has no effect on glycogen synthase activity.	MAPK8 MAPK9	1.49e-06	3	25	2	15013949
Pubmed	Arrestin-3 binds c-Jun N-terminal kinase 1 (JNK1) and JNK2 and facilitates the activation of these ubiquitous JNK isoforms in cells via scaffolding.	MAPK8 MAPK9	1.49e-06	3	25	2	24257757
Pubmed	MEK kinase 1 activity is required for definitive erythropoiesis in the mouse fetal liver.	MAPK8 MAPK9	1.49e-06	3	25	2	16081685
Pubmed	Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes.	MAPK8 MAPK9	1.49e-06	3	25	2	18971923
Pubmed	A central role for JNK in obesity and insulin resistance.	MAPK8 MAPK9	1.49e-06	3	25	2	12447443
Pubmed	Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis.	MAPK8 MAPK9	1.49e-06	3	25	2	19433446
Pubmed	JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis.	MAPK8 MAPK9	1.49e-06	3	25	2	21364637
Pubmed	JNK1 is required to preserve cardiac function in the early response to pressure overload.	MAPK8 MAPK9	1.49e-06	3	25	2	16579967
Pubmed	(-)-Epigallocatechin-3-gallate promotes pro-matrix metalloproteinase-7 production via activation of the JNK1/2 pathway in HT-29 human colorectal cancer cells.	MAPK8 MAPK9	1.49e-06	3	25	2	15860507
Pubmed	Both JNK1 and JNK2 Are Indispensable for Sensitized Extracellular Matrix Mineralization in IKKβ-Deficient Osteoblasts.	MAPK8 MAPK9	1.49e-06	3	25	2	32117051
Pubmed	Interaction of Neisseria meningitidis with human brain microvascular endothelial cells: role of MAP- and tyrosine kinases in invasion and inflammatory cytokine release.	MAPK8 MAPK9	1.49e-06	3	25	2	15527495
Pubmed	Dual specificity phosphatase16 is a negative regulator of c-Jun NH2-terminal kinase activity in T cells.	MAPK8 MAPK9	1.49e-06	3	25	2	20377744
Pubmed	The TAK1-JNK cascade is required for IRF3 function in the innate immune response.	MAPK8 MAPK9	1.49e-06	3	25	2	19153595
Pubmed	Specific pathophysiological functions of JNK isoforms in the brain.	MAPK8 MAPK9	1.49e-06	3	25	2	15673436
Pubmed	Role of JNK in a Trp53-dependent mouse model of breast cancer.	MAPK8 MAPK9	1.49e-06	3	25	2	20814571
Pubmed	c-Jun NH2-terminal kinase (JNK)1 and JNK2 have similar and stage-dependent roles in regulating T cell apoptosis and proliferation.	MAPK8 MAPK9	1.49e-06	3	25	2	11157052
Pubmed	JNK1 Induces Notch1 Expression to Regulate Genes Governing Photoreceptor Production.	MAPK8 MAPK9	1.49e-06	3	25	2	31450635
Pubmed	c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade.	MAPK8 MAPK9	1.49e-06	3	25	2	12417588
Pubmed	JNK phosphorylates beta-catenin and regulates adherens junctions.	MAPK8 MAPK9	1.49e-06	3	25	2	19667122
Pubmed	JNK2 modulates the CD1d-dependent and -independent activation of iNKT cells.	MAPK8 MAPK9	1.49e-06	3	25	2	30467836
Pubmed	Requirement of the JIP1 scaffold protein for stress-induced JNK activation.	MAPK8 MAPK9	1.49e-06	3	25	2	11562351
Pubmed	JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins.	MAPK8 MAPK9	1.49e-06	3	25	2	12689591
Pubmed	Cepharanthine triggers apoptosis in a human hepatocellular carcinoma cell line (HuH-7) through the activation of JNK1/2 and the downregulation of Akt.	MAPK8 MAPK9	1.49e-06	3	25	2	16412424
Pubmed	Melatonin attenuates osteosarcoma cell invasion by suppression of C-C motif chemokine ligand 24 through inhibition of the c-Jun N-terminal kinase pathway.	MAPK8 MAPK9	1.49e-06	3	25	2	29766567
Pubmed	Identification of nucleolar effects in JNK-deficient cells.	MAPK8 MAPK9	1.49e-06	3	25	2	18703060
Pubmed	JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation.	MAPK8 MAPK9	1.49e-06	3	25	2	8001819
Pubmed	Activation of c-Jun N-terminal kinase mediates gp120IIIB- and nucleoside analogue-induced sensory neuron toxicity.	MAPK8 MAPK9	1.49e-06	3	25	2	15246824
Pubmed	Inhibition of c-Jun NH2-terminal kinase stimulates mu opioid receptor expression via p38 MAPK-mediated nuclear NF-κB activation in neuronal and non-neuronal cells.	MAPK8 MAPK9	1.49e-06	3	25	2	23485395
Pubmed	Role of brain c-Jun N-terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a high-fat diet pre-clinical model.	MAPK8 MAPK9	1.49e-06	3	25	2	30734928
Pubmed	JNK2 is a positive regulator of the cJun transcription factor.	MAPK8 MAPK9	1.49e-06	3	25	2	16973441
Pubmed	Induction of hepatitis by JNK-mediated expression of TNF-alpha.	MAPK8 MAPK9	1.49e-06	3	25	2	19167327
Pubmed	Activation of JNK1/2 and p38 MAPK signaling pathways promotes enterovirus 71 infection in immature dendritic cells.	MAPK8 MAPK9	1.49e-06	3	25	2	24906853
Cytoband	Ensembl 112 genes in cytogenetic band chr13q12	CDX2 RNF17	7.18e-03	234	25	2	chr13q12
Cytoband	Ensembl 112 genes in cytogenetic band chr5q35	MAPK9 KCNIP1	7.24e-03	235	25	2	chr5q35
GeneFamily	Mitogen-activated protein kinases	MAPK8 MAPK9	9.95e-05	13	21	2	651
Coexpression	MCCLUNG_CREB1_TARGETS_DN	MAN1A1 TRHR LDB2	2.05e-05	56	25	3	M3576
Coexpression	MCCLUNG_CREB1_TARGETS_DN	MAN1A1 TRHR LDB2	2.53e-05	60	25	3	MM654
Coexpression	GSE22611_NOD2_VS_CTRL_TRANSDUCED_HEK293T_CELL_UP	TRPV1 PNKP LZTR1 MAN1A1	3.46e-05	197	25	4	M8166
ToppCell	Control-Neuronal_cells\|Control / group, cell type (main and fine annotations)	TMTC1 KCNIP1 GALNT18 LDB2	2.68e-06	176	25	4	c29d09ecf0eb17f767d78af4b7f2e7725c967ff8
ToppCell	Control-Neuronal_cells-Neuronal_cells\|Control / group, cell type (main and fine annotations)	TMTC1 KCNIP1 GALNT18 LDB2	2.68e-06	176	25	4	98c07d26ba0dc0fe15ca0ea81f633d4591782bd1
ToppCell	TCGA-Bile_Duct-Primary_Tumor-Cholangiocarcinoma-Intrahepatic\|TCGA-Bile_Duct / Sample_Type by Project: Shred V9	LZTR1 MAPK9 GALNT18 NOTCH2	4.46e-06	200	25	4	1fa8422fd820d21e285a7e7c4c6fbd8b7277d2af
ToppCell	frontal_cortex-Neuronal-glutamatergic_neuron-NP-L5_NP_ALM_Trhr_Nefl\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	TMTC1 TRHR LDB2	7.76e-05	149	25	3	558a441804dbcd5b5f39a3b1933b48976711ff15
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-NP-L5_NP_VISp_Trhr_Cpne7\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	TMTC1 TRHR KCNIP1	7.76e-05	149	25	3	8638b3819193d11411df58964069fec583f617f4
ToppCell	frontal_cortex-Neuronal-glutamatergic_neuron-NP\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	TMTC1 TRHR LDB2	7.92e-05	150	25	3	2ba55e51877e2e749cccdae7df5d885dc55b2587
ToppCell	Endothelial-endothelial_cell_of_bronchial_vessel\|World / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.05e-04	165	25	3	84e553d699ac56df89a77248f7308b9133e1b683
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 RNF17 LDB2	1.05e-04	165	25	3	a74751e0ec857aa974bec04ccc747c004a8f6e01
ToppCell	Children_(3_yrs)-Endothelial-endothelial_cell_of_vein-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.09e-04	167	25	3	d7fe24cdc4b55a9555ce9e20699f5036b88148e9
ToppCell	Endothelial-B-Donor_05\|World / lung cells shred on cell class, cell subclass, sample id	TMTC1 KCNIP1 GRK7	1.11e-04	168	25	3	4977c3837fbb1f36c89fddd5764e37290ac25ad8
ToppCell	Adult-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D122\|Adult / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.17e-04	171	25	3	bd20e85d36fa9d7ddc8afef6a1dea75efc9ee1dc
ToppCell	Control-Endothelial_cells-Systemic_venous_endothelial_cells\|Control / group, cell type (main and fine annotations)	TMTC1 GALNT18 LDB2	1.19e-04	172	25	3	c55dce1ed3ed7312394b4e050e1de852a994e130
ToppCell	Adult-Endothelial-endothelial_cell_of_bronchial_vessel\|Adult / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.19e-04	172	25	3	ad4ffdb3fc0c560a9cbaa2bc048476cbc43e8fd6
ToppCell	368C-Endothelial_cells-Endothelial-B_(Artery)\|368C / Donor, Lineage, Cell class and subclass (all cells)	TMTC1 GALNT18 LDB2	1.21e-04	173	25	3	22200fe74e33e2beae0eed289ca8476bbc0b1b2d
ToppCell	5'-Adult-LargeIntestine-Endothelial-lymphatic_endothelial-LEC3_(ADGRG3+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	KCNIP1 GALNT18 LDB2	1.21e-04	173	25	3	7dc988fc0ba29990567bf1bcdeb3faeeee507eb1
ToppCell	368C-Endothelial_cells-Endothelial-B_(Artery)-\|368C / Donor, Lineage, Cell class and subclass (all cells)	TMTC1 GALNT18 LDB2	1.21e-04	173	25	3	ec88e871b49331fca59bc610a8ae58e2d5e76bc1
ToppCell	metastatic_Lymph_Node-Endothelial_cells-Lymphatic_ECs\|metastatic_Lymph_Node / Location, Cell class and cell subclass	KCNIP1 GALNT18 LDB2	1.23e-04	174	25	3	d551bc29afef071adf4c9bb80345352ec33441d8
ToppCell	3'-Adult-LargeIntestine-Endothelial-lymphatic_endothelial-LEC3_(ADGRG3+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	KCNIP1 GALNT18 LDB2	1.27e-04	176	25	3	5d3b2395bb842eea39175f5af6a4c76527e2fc31
ToppCell	COVID-19-Heart-Lymph_EC\|COVID-19 / Disease (COVID-19 only), tissue and cell type	TMTC1 KCNIP1 LDB2	1.29e-04	177	25	3	326fde0734ef0d7272693966d346ca479b9d8147
ToppCell	COPD-Endothelial-VE_Venous\|World / Disease state, Lineage and Cell class	TMTC1 GALNT18 LDB2	1.34e-04	179	25	3	9968da1adcb561d9bf167a42ab5d9de85c071c4a
ToppCell	COVID-19-kidney-AQP1+SLC14A1+EC\|COVID-19 / Disease (COVID-19 only), tissue and cell type	TMTC1 GALNT18 LDB2	1.34e-04	179	25	3	1ce8d18f63e8dd2d3db41fbeca4601bd3b305fba
ToppCell	COVID-19-Heart-Lymph_EC\|Heart / Disease (COVID-19 only), tissue and cell type	MAN1A1 KCNIP1 LDB2	1.34e-04	179	25	3	411620201a860716a8773b92f50f7b94ef34a586
ToppCell	COVID-19-Heart-EC_2\|COVID-19 / Disease (COVID-19 only), tissue and cell type	TMTC1 GALNT18 LDB2	1.34e-04	179	25	3	2a53d94f6c30bf887dfe88f1693ea057218c852d
ToppCell	Children_(3_yrs)-Endothelial-endothelial_cell_of_vein-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.36e-04	180	25	3	27e8bbee388e64dd79d70b160b76d45b1f398006
ToppCell	COVID-19-Endothelial_cells-Endothelial_cells_(other)\|COVID-19 / group, cell type (main and fine annotations)	TMTC1 GALNT18 LDB2	1.38e-04	181	25	3	26eb4ee57a70dbf54e096b73129fda9dfda1f6ec
ToppCell	tumor_Lymph_Node_/_Brain-Endothelial_cells\|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass	TMTC1 GALNT18 LDB2	1.40e-04	182	25	3	d7cce5dd7046f06bf40f00c9dbfa610722b03333
ToppCell	Fetal_29-31_weeks-Endothelial-endothelial_cell_of_lymph_vessel-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.43e-04	183	25	3	bc98df870de65aff6dab295c24cbc199c7f2aa15
ToppCell	3'-Adult-SmallIntestine-Endothelial\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TMTC1 GALNT18 LDB2	1.43e-04	183	25	3	f8212bf8a8b8312434ae030261c558c147f61747
ToppCell	COVID-19-kidney-Mito-rich_EC\|kidney / Disease (COVID-19 only), tissue and cell type	TMTC1 GALNT18 LDB2	1.43e-04	183	25	3	3c4153479fc4ab2d073d92cee120480015555914
ToppCell	3'-Adult-SmallIntestine-Endothelial-blood_vessel_EC\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TMTC1 GALNT18 LDB2	1.43e-04	183	25	3	858682df5592c6856487487a7baabd6e60e63a38
ToppCell	COVID-19-Endothelial_cells-Arterial_endothelial_cells\|COVID-19 / group, cell type (main and fine annotations)	TMTC1 GALNT18 LDB2	1.45e-04	184	25	3	0f19494789f38ab1a420545e15e748ca7eb345c3
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_3\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	TMTC1 GALNT18 LDB2	1.45e-04	184	25	3	30fddbc9696476d4d7f08e53f84ea994a4ed873a
ToppCell	(6)_Endothelial-F_(Lymphatics)\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	KCNIP1 GALNT18 LDB2	1.45e-04	184	25	3	03ea613e00b45c81b752c14505a0538d698f551e
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_3-Exc_L2-3_LINC00507_RPL9P17\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	TMTC1 GALNT18 LDB2	1.45e-04	184	25	3	96926efa220f03d0787322c9519bb9e8f64f74d0
ToppCell	COPD-Endothelial-VE_Venous\|COPD / Disease state, Lineage and Cell class	TMTC1 GALNT18 LDB2	1.45e-04	184	25	3	44d716e7ba46a1ed03f5992631289653f8fd7d5e
ToppCell	COVID-19-Neuronal_cells\|COVID-19 / group, cell type (main and fine annotations)	KCNIP1 GALNT18 LDB2	1.47e-04	185	25	3	36ce23893915f5c380cca39b2c33a516edf31c3a
ToppCell	COVID-19-Endothelial_cells-Systemic_venous_endothelial_cells\|COVID-19 / group, cell type (main and fine annotations)	TMTC1 GALNT18 LDB2	1.47e-04	185	25	3	f5e14181f45c37d13ee9e017a4c8bc248c353676
ToppCell	COVID-19-Neuronal_cells-Neuronal_cells\|COVID-19 / group, cell type (main and fine annotations)	KCNIP1 GALNT18 LDB2	1.47e-04	185	25	3	4a095829992b39856a73bdfac03ee68b9aa0d3b8
ToppCell	Adult-Endothelial-capillary_endothelial_cell_(Cap1)-D231\|Adult / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.47e-04	185	25	3	07f9f38f0739d7c830641723a38385550ac1ac92
ToppCell	LPS-IL1RA-Endothelial-Endothelial-Activated_Gen_Cap\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TMTC1 GALNT18 LDB2	1.47e-04	185	25	3	808d5e880069aff8866cd2c733b9fe568a37701f
ToppCell	Control-Endothelial_cells-Endothelial_cells_(other)\|Control / group, cell type (main and fine annotations)	TMTC1 GALNT18 LDB2	1.50e-04	186	25	3	c6075fe84226b370c5139066793844ad33ae2db1
ToppCell	COVID-19-Heart-EC_2\|Heart / Disease (COVID-19 only), tissue and cell type	TMTC1 GALNT18 LDB2	1.52e-04	187	25	3	40ffc06a3e3251d9b12da390210d3e045af7537a
ToppCell	Adult-Endothelial-capillary_endothelial_cell_(Cap1)-D175\|Adult / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.52e-04	187	25	3	f3548817f2fded5978137bb252cb628ac199e4f6
ToppCell	LV-10._Endothelium_II\|World / Chamber and Cluster_Paper	TMTC1 GALNT18 LDB2	1.52e-04	187	25	3	7876dcb4800c2e54874df3d933efb79307a64a97
ToppCell	tumor_Lung-Endothelial_cells-Lymphatic_ECs\|tumor_Lung / Location, Cell class and cell subclass	KCNIP1 GALNT18 LDB2	1.52e-04	187	25	3	87ecdc5f24aced95a37e653429f0fc493ff4aa3e
ToppCell	Adult-Endothelial-endothelial_cell_of_lymph_vessel-D175\|Adult / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.52e-04	187	25	3	1e52d3d9d664c813d859b5b75e4c07b218818f95
ToppCell	tumor_Lymph_Node_/_Brain-Endothelial_cells-Tumor_ECs\|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass	TMTC1 GALNT18 LDB2	1.52e-04	187	25	3	be5f8c5802b0fa8cc1e274fdf06b13eb8ceb8ad4
ToppCell	Control-Endothelial_cells-Endothelial_cells_(general)\|Control / group, cell type (main and fine annotations)	TMTC1 GALNT18 LDB2	1.52e-04	187	25	3	fb5bcbc8effdbf0e57fcb71aca990a4aa0d65ce8
ToppCell	COVID-19-Endothelial_cells-Pulmonary_venous_endothelial_cells\|COVID-19 / group, cell type (main and fine annotations)	TMTC1 GALNT18 LDB2	1.52e-04	187	25	3	2d20193a6cacdfa4877457c97b0077408942186c
ToppCell	Children_(3_yrs)-Endothelial-endothelial_cell_of_vein\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.52e-04	187	25	3	e35716f8b482be3bf5ab79f087a9caf67a9d197a
ToppCell	Adult-Endothelial-capillary_endothelial_cell_(Cap1)-D122\|Adult / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.54e-04	188	25	3	02a62888e9db29d20133eeca1686d302545a39c9
ToppCell	390C-Endothelial_cells-Endothelial-F_(Lymphatics)-\|390C / Donor, Lineage, Cell class and subclass (all cells)	KCNIP1 GALNT18 LDB2	1.54e-04	188	25	3	1f40b959777d18ad88d239df8cca304f062ba04c
ToppCell	Control-Endothelial_cells\|Control / group, cell type (main and fine annotations)	TMTC1 GALNT18 LDB2	1.54e-04	188	25	3	3953b08abfea93468fc8d177bdb16ca7c6ffa1ab
ToppCell	Control-Endothelial-VE_Peribronchial\|Control / Disease state, Lineage and Cell class	TMTC1 GALNT18 LDB2	1.54e-04	188	25	3	f5b7dbc89f992c13280d36a34935be83906b1bc0
ToppCell	Endothelial-endothelial_cell_of_lymph_vessel\|World / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.54e-04	188	25	3	80910dcbb51990f2baed240f319456c0d3fa2065
ToppCell	Endothelial-B\|World / lung cells shred on cell class, cell subclass, sample id	TMTC1 KCNIP1 LDB2	1.54e-04	188	25	3	5959a88728812a5f4cbfa54eddc7a73ccbaa2f68
ToppCell	Children_(3_yrs)-Endothelial-endothelial_cell_of_lymph_vessel-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.54e-04	188	25	3	2db80767903703e7e0a1a37c598f7877a909ee94
ToppCell	COVID-19-lung-Vein_EC\|lung / Disease (COVID-19 only), tissue and cell type	TMTC1 GALNT18 LDB2	1.54e-04	188	25	3	d582b76fc2faac526c9bf97503041129e1a6a211
ToppCell	COVID-19-lung-Artery_EC\|lung / Disease (COVID-19 only), tissue and cell type	TMTC1 GALNT18 LDB2	1.54e-04	188	25	3	eecd7482b3c97d7f49993cb17edfab30c61232fc
ToppCell	Children_(3_yrs)-Endothelial-endothelial_cell_of_lymph_vessel\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.54e-04	188	25	3	c2805232618a7b6f844d34e37ad458a9923dbfe1
ToppCell	390C-Endothelial_cells-Endothelial-F_(Lymphatics)\|390C / Donor, Lineage, Cell class and subclass (all cells)	KCNIP1 GALNT18 LDB2	1.54e-04	188	25	3	aa69e3f44d506f5ef358a3374ac5160d847c858f
ToppCell	Children_(3_yrs)-Endothelial-endothelial_cell_of_lymph_vessel-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.54e-04	188	25	3	aeecbc057dc823f8fcea8a98f18d213bacc7f4db
ToppCell	Fetal_29-31_weeks-Endothelial-endothelial_cell_of_lymph_vessel\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	TMTC1 KCNIP1 LDB2	1.57e-04	189	25	3	55a1776a4ce049959b3f13a43744c7314bc1f00a
ToppCell	Control-Endothelial-VE_Peribronchial\|World / Disease state, Lineage and Cell class	TMTC1 GALNT18 LDB2	1.57e-04	189	25	3	c76d8af2e0aa4a83ee0c3439c894566fbf117dd3
ToppCell	Fetal_29-31_weeks-Endothelial-endothelial_cell_of_lymph_vessel-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	TMTC1 KCNIP1 LDB2	1.57e-04	189	25	3	0d18ea72bd58d32a8ab9a61cf97f5786642f804b
ToppCell	COVID-19-Heart-EC_1\|COVID-19 / Disease (COVID-19 only), tissue and cell type	TMTC1 GALNT18 LDB2	1.57e-04	189	25	3	fe49852ba15f948b384d6b4c258927c70b741357
ToppCell	Children_(3_yrs)-Endothelial-endothelial_cell_of_lymph_vessel-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.59e-04	190	25	3	6e6ce6dd549d1c38cfef5b3f8be06ab01ce344b7
ToppCell	COVID-19-lung-Artery_EC\|COVID-19 / Disease (COVID-19 only), tissue and cell type	TMTC1 GALNT18 LDB2	1.59e-04	190	25	3	07b675befcd1d0a9c90cb17b5d22323468325d51
ToppCell	3'-Parenchyma_lung-Endothelial-Blood_vessel_EC-pulmonary_artery_endothelial_cell-EC_arterial-EC_arterial_L.2.4.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	TMTC1 XPNPEP2 LDB2	1.59e-04	190	25	3	d0297d678498e346e56cf95fe9e3db7d3ad3b837
ToppCell	human_hepatoblastoma-Endothelial_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	TMTC1 GALNT18 LDB2	1.59e-04	190	25	3	8d6ef93d69e96cd6921816d152bea3b0710cf147
ToppCell	COVID-19-Endothelial_cells\|COVID-19 / group, cell type (main and fine annotations)	TMTC1 GALNT18 LDB2	1.59e-04	190	25	3	9fbd92cd6d4683b2490504d29c43cf42020433d4
ToppCell	COVID-19-Endothelial_cells-Endothelial_cells_(general)\|COVID-19 / group, cell type (main and fine annotations)	TMTC1 GALNT18 LDB2	1.59e-04	190	25	3	812e11314c76c0179fbe5a9bea29b41ce5cbc93d
ToppCell	COVID-19-Heart-EC_3\|Heart / Disease (COVID-19 only), tissue and cell type	TMTC1 GALNT18 LDB2	1.59e-04	190	25	3	78e7c502b0450c0b37652b1896a2a752fd8a2111
ToppCell	COVID-19-Heart-EC_+_Pericyte\|Heart / Disease (COVID-19 only), tissue and cell type	TMTC1 GALNT18 LDB2	1.59e-04	190	25	3	a21653bfb7bafbc273f94fa7c13bfb48cf8fd562
ToppCell	COVID-19-lung-Vein_EC\|COVID-19 / Disease (COVID-19 only), tissue and cell type	TMTC1 GALNT18 LDB2	1.59e-04	190	25	3	1caeaef78326734c1e31a0c4739190d5c5a77b9e
ToppCell	Control-Endothelial-VE_Capillary_B\|Control / Disease state, Lineage and Cell class	TMTC1 GALNT18 LDB2	1.62e-04	191	25	3	322237793a1278bafb14e63cab688b353e352dcc
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 KCNIP1 LDB2	1.62e-04	191	25	3	a58c75e9580139fb370b498d95660f10f3a2a27b
ToppCell	Control-Endothelial-VE_Capillary_B\|World / Disease state, Lineage and Cell class	TMTC1 GALNT18 LDB2	1.62e-04	191	25	3	c672c8e28d06d555335976b3f8bd2ea6d3b34aae
ToppCell	RA-09._Endothelium_I\|World / Chamber and Cluster_Paper	TMTC1 GALNT18 LDB2	1.62e-04	191	25	3	c8a0c2af119bc34a8f694a7d30642f28002c84b9
ToppCell	LPS_only-Endothelial-Endothelial-Vein\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TMTC1 GALNT18 LDB2	1.64e-04	192	25	3	52acaecd3703166f5ce3b328aff7c82bd142fee4
ToppCell	IPF-Endothelial-Lymphatic\|IPF / Disease state, Lineage and Cell class	TMTC1 GALNT18 LDB2	1.64e-04	192	25	3	2496edd8f3a41146d418879de9ee2ccc7857431f
ToppCell	RA-09._Endothelium_I\|RA / Chamber and Cluster_Paper	TMTC1 GALNT18 LDB2	1.64e-04	192	25	3	8a1b1c3e83a68ad74f8f4eb00455c9e41aa57cfc
ToppCell	renal_papilla_nuclei-Adult_normal_reference\|renal_papilla_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group	TMTC1 MAN1A1 LDB2	1.64e-04	192	25	3	6c106b91e46eabbe686a52a65a9c94ad9cbe9390
ToppCell	LPS-IL1RA-Endothelial-Endothelial-Vein\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TMTC1 GALNT18 LDB2	1.64e-04	192	25	3	717f3d3bbee4d0f64ba1341ee2b00a407ba1e0f3
ToppCell	Control-Endothelial-Lymphatic\|World / Disease state, Lineage and Cell class	TMTC1 GALNT18 LDB2	1.64e-04	192	25	3	f95fb188aa642f3d0618242a770e7c4b70544adb
ToppCell	LPS-antiTNF-Endothelial-Endothelial-Vein\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TMTC1 GALNT18 LDB2	1.64e-04	192	25	3	81baf1c4063469bb0c03a8602b40e387ba7b0dfb
ToppCell	COVID-19-kidney-AQP1+PLVAP+EC\|COVID-19 / Disease (COVID-19 only), tissue and cell type	TMTC1 GALNT18 LDB2	1.64e-04	192	25	3	27ff3621e177e7932dd44dd6baa81551ea75a874
ToppCell	human_hepatoblastoma-Endothelial_cells\|human_hepatoblastoma / Sample and Cell Type and Tumor Cluster (all cells)	TMTC1 GALNT18 LDB2	1.64e-04	192	25	3	e09f609fed033a25baacaf4a07bbbae1076da366
ToppCell	nucseq-Endothelial-Endothelial_Vascular-Endothelial_capillary\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TMTC1 GALNT18 LDB2	1.67e-04	193	25	3	f582e939e3e08a8a3f71deec78c33715be8faa51
ToppCell	Control-Endothelial-Lymphatic\|Control / Disease state, Lineage and Cell class	TMTC1 GALNT18 LDB2	1.67e-04	193	25	3	64d19be73e5432d491436a01da5de5c926b615a9
ToppCell	Control-Fibroblasts-Vascular_smooth_muscle\|Control / group, cell type (main and fine annotations)	TMTC1 GALNT18 LDB2	1.67e-04	193	25	3	60e44aac8be0430ad35e20eb98b1b700d76a0427
ToppCell	nucseq-Endothelial-Endothelial_Vascular-Endothelial_capillary-CAP1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TMTC1 GALNT18 LDB2	1.67e-04	193	25	3	ad3f4fcc8e2816d696cbcde744dc16500e51ccac
ToppCell	Adult-Endothelial-capillary_endothelial_cell_(Cap1)\|Adult / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.67e-04	193	25	3	39c6c96a2a100b1b290a779d36cc6bc17245720b
ToppCell	IPF-Endothelial-VE_Capillary_B\|World / Disease state, Lineage and Cell class	TMTC1 GALNT18 LDB2	1.67e-04	193	25	3	d7750a7575ef257963b7f1c64fa67c52dbff797b
ToppCell	LPS-IL1RA+antiTNF-Endothelial-Endothelial-Vein\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TMTC1 GALNT18 LDB2	1.67e-04	193	25	3	7261c1ce30c796b61c6ec58e64a051baa24732ff
ToppCell	IPF-Endothelial-VE_Venous\|IPF / Disease state, Lineage and Cell class	TMTC1 GALNT18 LDB2	1.67e-04	193	25	3	29a655fa80feaabe846c90a28363b037e22d24ae
ToppCell	RV-09._Endothelium_I\|World / Chamber and Cluster_Paper	TMTC1 GALNT18 LDB2	1.67e-04	193	25	3	e3fa47e2c7cd8a5b69186711c57751f2296de8ae
ToppCell	IPF-Endothelial-VE_Venous\|World / Disease state, Lineage and Cell class	TMTC1 GALNT18 LDB2	1.67e-04	193	25	3	ef66a46e7ab44fcc4005a23416e6da478a4cce37
ToppCell	Children_(3_yrs)-Endothelial-capillary_endothelial_cell_(Cap1)\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.69e-04	194	25	3	71ac69cdf7a08ca3ddfb5b492b14ac56b6cd5e5d
ToppCell	Children_(3_yrs)-Endothelial-capillary_endothelial_cell_(Cap1)-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TMTC1 GALNT18 LDB2	1.69e-04	194	25	3	68004855b23fe1e31e8452d70effabc78a4a0bd3
Drug	Tetracaine	TRPV1 MAPK8 MAPK9	2.56e-07	12	25	3	ctd:D013748
Drug	resiniferatoxin	TRPV1 MAPK8 MAPK9	9.44e-07	18	25	3	ctd:C024353
Drug	CPG-oligonucleotide	PNKP PRKDC MAPK8 MAPK9 MPG	1.52e-06	184	25	5	ctd:C408982
Drug	CGC 11093	MAPK8 MAPK9	3.47e-06	3	25	2	ctd:C515676
Drug	benzothiazol-2-ylacetonitrile	MAPK8 MAPK9	3.47e-06	3	25	2	CID000342465
Drug	benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone	PRKDC MAPK8 MAPK9	4.19e-06	29	25	3	ctd:C403753
Drug	Uranyl Nitrate	MAPK8 MAPK9 TF	5.15e-06	31	25	3	ctd:D014502
Drug	O(2)-(2,4-dinitrophenyl) 1-(4-(N,N-diethylcarboxamido)piperazin-1-yl)diazen-1-ium 1,2-diolate	MAPK8 MAPK9	6.94e-06	4	25	2	ctd:C495194
Drug	AC1L9CMN	MAPK8 MAPK9	1.16e-05	5	25	2	CID000442339
Drug	AC1MJ5N7	MAPK8 MAPK9	1.16e-05	5	25	2	CID003086135
Drug	ovatodiolide	MAPK8 MAPK9	1.16e-05	5	25	2	ctd:C432447
Drug	AC1O4QII	PNKP MAPK8 MAPK9	1.50e-05	44	25	3	CID006398468
Drug	indole-5-carboxamide	MAPK8 MAPK9	1.73e-05	6	25	2	ctd:C514526
Drug	Vinyl Compounds	MAPK8 MAPK9	1.73e-05	6	25	2	ctd:D014753
Drug	pramipexole	MAPK8 MAPK9	1.73e-05	6	25	2	ctd:C061333
Drug	Eosine I Bluish	MAPK8 MAPK9	1.73e-05	6	25	2	ctd:D010697
Drug	AC1L3ZTY	MAPK8 MAPK9	2.42e-05	7	25	2	CID000098120
Drug	LL Z1640-2	MAPK8 MAPK9	2.42e-05	7	25	2	ctd:C118715
Drug	2-(4-((dimethylamino)methyl)benzylidene)-5,6-dimethoxy-2,3-dihydroinden-1-one	MAPK8 MAPK9	2.42e-05	7	25	2	ctd:C543150
Drug	iomeprol	MAPK8 MAPK9	2.42e-05	7	25	2	ctd:C057937
Drug	poly(N-vinylpyrrolidine)	MAPK8 MAPK9	2.42e-05	7	25	2	ctd:C505150
Drug	fludelone	MAPK8 MAPK9	2.42e-05	7	25	2	CID006918712
Drug	SB366791	TRPV1 MAPK9	2.42e-05	7	25	2	CID000667594
Drug	eupafolin	MAPK8 MAPK9	3.23e-05	8	25	2	ctd:C503624
Drug	Silicates	MAPK8 MAPK9	3.23e-05	8	25	2	ctd:D017640
Drug	methyldiazonium ion	MAPK8 MAPK9	3.23e-05	8	25	2	CID000115287
Drug	caffeoylquinic acid	MAPK8 MAPK9	3.23e-05	8	25	2	ctd:C472707
Drug	tyrphostin A9	MAPK8 MAPK9	3.23e-05	8	25	2	ctd:C406122
Drug	desisobutyrylciclesonide	MAPK8 MAPK9	3.23e-05	8	25	2	ctd:C494355
Drug	trapidil	PRKACG MAPK8 MAPK9	3.29e-05	57	25	3	CID000005531
Drug	Win 55212-2	TRPV1 MAPK8 MAPK9	3.47e-05	58	25	3	ctd:C070417
Drug	2''-galloylhyperin	MAPK8 MAPK9	4.15e-05	9	25	2	ctd:C087939
Drug	S 52	MAPK8 MAPK9	4.15e-05	9	25	2	CID000023681
Drug	AC1L6EKE	MAPK8 MAPK9	4.15e-05	9	25	2	CID000265720
Drug	methyl methanesulfonate	PNKP PRKDC MAPK8 MAPK9 MPG	4.15e-05	364	25	5	CID000004156
Drug	Egtazic Acid	TRPV1 MAPK8 MAPK9	4.24e-05	62	25	3	ctd:D004533
Drug	osmium tetroxide	PNKP MAPK8 MAPK9	4.66e-05	64	25	3	CID000030318
Drug	D-JNKI-1	MAPK8 MAPK9	5.18e-05	10	25	2	ctd:C478085
Drug	alpha-chaconine	MAPK8 MAPK9	5.18e-05	10	25	2	ctd:C011860
Drug	3-O-caffeoyl-1-methylquinic acid	MAPK8 MAPK9	5.18e-05	10	25	2	ctd:C490257
Drug	6,7-dimethoxy-3-phenylquinoxaline	MAPK8 MAPK9	5.18e-05	10	25	2	ctd:C106250
Drug	irisolidone	MAPK8 MAPK9	5.18e-05	10	25	2	CID005281781
Drug	Go6976	PRKACG PRKDC MAPK8 MAPK9	5.18e-05	190	25	4	CID000003501
Drug	AC1L96VB	TRPV1 PNKP MAPK8 MAPK9	5.29e-05	191	25	4	CID000439200
Drug	Polysaccharides	MAPK8 MAPK9 TF	5.59e-05	68	25	3	ctd:D011134
Drug	Rapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA	TRPV1 LZTR1 MAPK8 SLC15A2	5.62e-05	194	25	4	1001_UP
Drug	Pipenzolate bromide [125-51-9]; Up 200; 9.2uM; PC3; HT_HG-U133A	PRKACG XPNPEP2 RNF17 KCNIP1	5.85e-05	196	25	4	4484_UP
Drug	Metyrapone [54-36-4]; Down 200; 17.6uM; HL60; HT_HG-U133A	TRPV1 MAN1A1 MAPK8 NOTCH2	5.96e-05	197	25	4	3070_DN
Drug	Thiorphan [76721-89-6]; Up 200; 15.8uM; MCF7; HT_HG-U133A	XPNPEP2 MAPK8 RNF17 KCNIP1	5.96e-05	197	25	4	2752_UP
Drug	Furazolidone [67-45-8]; Down 200; 17.8uM; HL60; HT_HG-U133A	TRPV1 MAN1A1 SLC15A2 NOTCH2	5.96e-05	197	25	4	3019_DN
Drug	LY 294002; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA	TRPV1 LZTR1 SLC15A2 NOTCH2	6.08e-05	198	25	4	996_UP
Drug	Flavoxate hydrochloride [3717-88-2]; Up 200; 9.4uM; PC3; HT_HG-U133A	PRKACG MAN1A1 SNAPC4 KCNIP1	6.08e-05	198	25	4	6326_UP
Drug	SR144528	TRPV1 MAPK8 MAPK9	6.10e-05	70	25	3	CID003081355
Drug	Diloxanide furoate [3736-81-0]; Down 200; 12.2uM; HL60; HT_HG-U133A	TRPV1 LZTR1 MAPK8 NOTCH2	6.32e-05	200	25	4	3062_DN
Drug	soyasaponin Ab	MAPK8 MAPK9	6.33e-05	11	25	2	ctd:C551307
Drug	N(6),N(6)-dimethyladenine	MAPK8 MAPK9	6.33e-05	11	25	2	ctd:C001020
Drug	Wen-pi-tang-Hab-Wu-ling-san	MAPK8 MAPK9	6.33e-05	11	25	2	ctd:C521629
Drug	AC1NURR2	MAPK8 MAPK9	6.33e-05	11	25	2	CID005490351
Drug	hexandiol	PNKP MPG	6.33e-05	11	25	2	CID000147023
Drug	VI-14 flavonoid	MAPK8 MAPK9	6.33e-05	11	25	2	ctd:C573672
Drug	9-CP-Ade	MAPK8 MAPK9	6.33e-05	11	25	2	CID000012852
Drug	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	TRPV1 CDX2 MAPK8 MAPK9 TF	6.49e-05	400	25	5	ctd:C085911
Drug	Masoprocol	TRPV1 MAPK8 MAPK9	7.20e-05	74	25	3	ctd:D009637
Drug	dinitrophenyl-bovine serum albumin	MAPK8 MAPK9	7.59e-05	12	25	2	ctd:C034638
Drug	N-Acetylcysteinamide	MAPK8 MAPK9	7.59e-05	12	25	2	ctd:C487056
Drug	anthrapyrazole	MAPK8 MAPK9	7.59e-05	12	25	2	CID000119330
Drug	2-aminodiphenyl	MAPK8 MAPK9	7.59e-05	12	25	2	ctd:C014970
Drug	Zinostatino	PNKP PRKDC TF	8.43e-05	78	25	3	CID005282473
Drug	Caspase Inhibitor I	PRKDC MAPK8 MAPK9	8.43e-05	78	25	3	CID000004339
Drug	azaspiracid	MAPK8 MAPK9	8.96e-05	13	25	2	ctd:C406592
Drug	SCIO-469	MAPK8 MAPK9	8.96e-05	13	25	2	ctd:C499748
Drug	H 1356	MAPK8 MAPK9	8.96e-05	13	25	2	ctd:C411572
Drug	Guanosine	MAPK8 MAPK9	8.96e-05	13	25	2	ctd:D006151
Drug	Cytotoxins	MAPK8 MAPK9	8.96e-05	13	25	2	ctd:D003603
Drug	N-arachidonoylethanolamine	TRPV1 MAPK8 MAPK9 MPG	1.02e-04	226	25	4	CID000002185
Drug	farnesylamine	MAPK8 MAPK9	1.04e-04	14	25	2	CID006449783
Drug	oleoylethanolamide	TRPV1 MAPK8	1.04e-04	14	25	2	ctd:C488250
Drug	5-((4-methylphenyl)methylene)-2-(phenylamino)-4(5H)-thiazolone	MAPK8 MAPK9	1.04e-04	14	25	2	ctd:C503119
Drug	K2PtCl4	PNKP TF	1.04e-04	14	25	2	CID003013632
Drug	AC1L1L12	PNKP MPG	1.04e-04	14	25	2	CID000005738
Drug	AC1NUZLU	PRKDC LZTR1 MAPK8 MAPK9	1.16e-04	234	25	4	CID005497170
Drug	2-chloroethyl ethyl sulfide	MAPK8 MAPK9 MPG	1.17e-04	87	25	3	ctd:C031278
Drug	LY 293111	MAPK8 MAPK9	1.20e-04	15	25	2	ctd:C094099
Drug	methyl 3-hydroxyimino-11-oxoolean-12-en-28-oate	MAPK8 MAPK9	1.20e-04	15	25	2	ctd:C587228
Drug	1-((1-O-octadecyl-2-O-methylglycero)phospho)-3-deoxy-myo-inositol	MAPK8 MAPK9	1.20e-04	15	25	2	ctd:C435044
Drug	E-4IB	MAPK8 MAPK9	1.20e-04	15	25	2	CID000123372
Drug	puag-haad	MAPK8 MAPK9	1.20e-04	15	25	2	ctd:C034912
Drug	ethenocytosine	PNKP MPG	1.20e-04	15	25	2	CID000124300
Drug	Chromium	PRKDC MAPK8 MAPK9 TF	1.24e-04	238	25	4	ctd:D002857
Drug	labedipinedilol A	MAPK8 MAPK9	1.38e-04	16	25	2	ctd:C500368
Drug	dracorhodin	MAPK8 MAPK9	1.38e-04	16	25	2	ctd:C060327
Drug	aniline	MAPK8 MAPK9 TF	1.38e-04	92	25	3	ctd:C023650
Drug	pifithrin	PRKDC MAPK8 MAPK9	1.51e-04	95	25	3	ctd:C121565
Drug	Ambotz208527-57-5	MAPK8 MAPK9	1.56e-04	17	25	2	CID010258704
Drug	O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate	MAPK8 MAPK9	1.56e-04	17	25	2	ctd:C474958
Drug	Diatrizoate	MAPK8 MAPK9	1.56e-04	17	25	2	ctd:D003973
Drug	Eicosapentaenoic Acid	TRPV1 MAPK8 MAPK9	1.56e-04	96	25	3	ctd:D015118
Drug	Gallic Acid	PRKDC MAPK8 MAPK9	1.61e-04	97	25	3	ctd:D005707
Drug	3-nonenal	MAPK8 MAPK9	1.75e-04	18	25	2	CID005283336
Drug	NSC363979	MAPK8 MAPK9	1.75e-04	18	25	2	CID000183413
Disease	Secondary Trigeminal Neuralgia	MAPK8 MAPK9	4.52e-05	12	25	2	C0393787
Disease	Trigeminal Neuralgia, Idiopathic	MAPK8 MAPK9	4.52e-05	12	25	2	C0393786
Disease	Trigeminal Neuralgia	MAPK8 MAPK9	4.52e-05	12	25	2	C0040997
Disease	Mechanical Allodynia	TRPV1 MAPK8 MAPK9	4.89e-05	84	25	3	C2936719
Disease	Hyperalgesia	TRPV1 MAPK8 MAPK9	4.89e-05	84	25	3	C0020429
Disease	Allodynia	TRPV1 MAPK8 MAPK9	4.89e-05	84	25	3	C0458247
Disease	Hyperalgesia, Secondary	TRPV1 MAPK8 MAPK9	4.89e-05	84	25	3	C0751212
Disease	Hyperalgesia, Primary	TRPV1 MAPK8 MAPK9	4.89e-05	84	25	3	C0751211
Disease	Hyperalgesia, Thermal	TRPV1 MAPK8 MAPK9	4.89e-05	84	25	3	C0751214
Disease	Tactile Allodynia	TRPV1 MAPK8 MAPK9	4.89e-05	84	25	3	C0751213
Disease	Precancerous Conditions	CDX2 MAPK8 MAPK9	1.09e-04	110	25	3	C0032927
Disease	Condition, Preneoplastic	CDX2 MAPK8 MAPK9	1.09e-04	110	25	3	C0282313
Disease	Glioblastoma Multiforme	LZTR1 MAPK8 NOTCH2	1.12e-04	111	25	3	C1621958
Disease	Cholestasis, Extrahepatic	MAPK8 MAPK9	3.37e-04	32	25	2	C0005398
Disease	alcohol use disorder (implicated_via_orthology)	PRKACG GRK7 NOTCH2	5.87e-04	195	25	3	DOID:1574 (implicated_via_orthology)
Disease	Adenocarcinoma of lung (disorder)	PRKDC SLC15A2 TF	6.89e-04	206	25	3	C0152013
Disease	Metastatic melanoma	PRKDC GRK7	9.60e-04	54	25	2	C0278883

Protein segments in the cluster

Peptide	Gene	Start	Entry
MYVSYLLDKDVSMYP	CDX2	1	Q99626
MAVPTIYTKLMEYYD	ACSF3	291	Q4G176
MMTPYVVTRYYRAPE	MAPK9	181	P45984
ELMVYPYYGEKSAAM	NOTCH2	1586	Q04721
ESMLRYIYYGEVNMP	LZTR1	721	Q8N653
HTPYMVQPEYRIYEM	LDB2	21	O43679
MMTPYVVTRYYRAPE	MAPK8	181	P45983
AVRTPYTMGYGESMY	RBM4B	196	Q9BQ04
IVKAIYDMMGKYTYP	KCNIP1	161	Q9NZI2
YDMMGKYTYPVLKED	KCNIP1	166	Q9NZI2
YLYLVMEYVPGGEMF	PRKACG	116	P22612
SVYPEMRMYSDIIAY	GALNT18	456	Q6P9A2
MKPGTLYVYIIYGMY	MPG	151	P29372
YYILRPEVMETYMYM	MAN1A1	541	P33908
PEMYKIFTMAEVYGI	IPO9	191	Q96P70
YMAPEILMEKVSYSY	GRK7	356	Q8WTQ7
IMGYYYVPVKTEDMR	SLC15A2	691	Q16348
IYLMDFGVFYVVPMI	TRHR	191	P34981
DMVMYGYRKQFEAPT	PNKP	476	Q96T60
YYPMAGYIKEDSIME	RNF17	86	Q9BXT8
PRMDAKMYLGYEYVT	TF	326	P02787
FVVAERVLYMPSMGY	TMTC1	406	Q8IUR5
MIIFTMAAYYRPVDG	TRPV1	446	Q8NER1
MGYYKILDVMYSRLP	PRKDC	1871	P78527
PYRRIVYYMEGRDSM	SNAPC4	371	Q5SXM2
TSYTMYGIYEMIPKE	XPNPEP2	326	O43895